Form 4: Jasper Therapeutics Director Kurt Von Emster Receives Stock Option Grant

Kurt Von Emster, a Director and 10% Owner of Jasper Therapeutics, Inc., was granted an option to purchase 7,500 shares of common stock at an exercise price of $6.77 per share, effective July 3, 2025.

Summary

• Kurt Von Emster, a Director and 10% Owner of Jasper Therapeutics, Inc. (JSPR), was granted a stock option.
• The option allows the purchase of 7,500 shares of Voting Common Stock.
• The exercise price for the option is $6.77 per share.
• The transaction date for this grant is July 3, 2025.
• The option becomes exercisable on July 3, 2026, and expires on July 3, 2035.
• This grant was made automatically under the Issuer's Non-Employee Director Compensation Policy, which provides for a 7,500-share option grant on the date of each annual meeting of stockholders.
• Following this transaction, Kurt Von Emster beneficially owns 7,500 derivative securities directly.

Sentiment

Score: 6

Explanation: The document reports a routine, expected stock option grant to a director as part of a compensation policy. This is generally a neutral to slightly positive event as it aligns director incentives with shareholder interests, without indicating any immediate negative financial implications or significant strategic shifts.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value.
• The transaction is part of a pre-established Non-Employee Director Compensation Policy, indicating a structured approach to executive incentives.

Negatives

• The issuance of new options could lead to minor share dilution if exercised in the future.

Risks

• Potential future dilution of existing shares if the granted stock options are exercised.

Future Outlook

The stock option has a future exercisable date of July 3, 2026, and an expiration date of July 3, 2035, indicating a long-term incentive structure.

Industry Context

This type of stock option grant to a non-employee director is a standard practice in the biotechnology and pharmaceutical industries, aligning director incentives with company performance and shareholder interests over the long term.

Comparison to Industry Standards

• The grant of 7,500 stock options to a non-employee director is a common form of compensation in the biotech sector, comparable to practices at similar-sized companies where equity incentives are used to attract and retain qualified board members. Specific comparable companies or projects are not detailed in this filing.

Corporate Governance

Related Party Transactions

• Kurt Von Emster, a Director and 10% Owner, received a stock option grant from Jasper Therapeutics, Inc. as part of his compensation.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from aligned director incentives.
• Director (Kurt Von Emster): Receives equity-based compensation, aligning personal financial interests with company performance.

Next Steps

• The stock option will become exercisable on July 3, 2026.

Key Dates

Keywords

Jasper Therapeutics, JSPR, SEC Form 4, Stock Option, Director Compensation, Insider Transaction, Equity Grant, Kurt Von Emster